Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis
Helicobacter · 2023
DOI: 10.1111/hel.13003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Helicobacter, 2023. Verfasst von Na-Yun Su und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University, Third Military Medical …. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission.
Abstract (Originalsprache)
Background
According to the Maastricht VI/Florence consensus report, potassium‐competitive acid blockers (P‐CAB) may improve Helicobacter pylori eradication treatment. Materials and methods A total of 213 H. pylori treatment‐naive patients aged between 18 and 70 years were treated with two regimens. The two regimens are VDT: 20 mg vonoprazan twice a day and 1 g amoxicillin three times daily and EDT: 20 mg esomeprazole four times a day and 750 mg amoxicillin four times daily. 13 C‐urea breath tests were used to evaluate eradication rate 4–6 weeks after treatment. Based on propensity score matching (PSM), this retrospective study analyzed the eradication rates, adverse events (AEs), compliance, and antibiotic resistance rates in VDT and EDT groups.
Results
On intention‐to‐treat (ITT) analysis, the eradication rate in VDT group (89.0%; 95% CI 81.7–96.3) was non‐inferior to that in EDT group (87.7%; 95% CI 80.1–95.3; p = 0.796). The corresponding per‐protocol (PP) eradication rates were 94.1% (95% CI 88.4–99.8) and 92.8% (95% CI 86.7–98.9; p = 1.000), respectively. There were no significant between‐group differences with respect to compliance or incidence of AEs.
Conclusions
The efficacy and safety of 14‐day VDT and EDT were comparable. Therefore, 14‐day VDT or EDT may be recommended for the first‐line treatment of H. pylori infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University, Third Military Medical University, Chongqing, China.
ORCID-Profile: Na-Yun Su, Chun-Hui Lan
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission
Zitieren
APA
Su, N. Y., Shi, Q., Mei, H., Hu, J., Liu, Y. X., Liu, H. N., Liu, H. Q., Guo, Y., Wang, X. W., & Lan, C. H. (2023). Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis. Helicobacter. https://doi.org/10.1111/hel.13003
Vancouver
Su NY, Shi Q, Mei H, Hu J, Liu YX, Liu HN, et al. Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis. Helicobacter. 2023. doi:10.1111/hel.13003
BibTeX
@article{Su2023,
author = {Su, Na-Yun and Shi, Qing and Mei, Hao and Hu, Jie and Liu, Yu-Xiang and Liu, Han-Ning and Liu, Heng-Qi and Guo, Yan and Wang, Xing-Wei and Lan, Chun-Hui},
title = {Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis},
journal = {Helicobacter},
year = {2023},
doi = {10.1111/hel.13003}
}
EUVIMED